Donor Risk Index for African American Liver Transplant Recipients With Hepatitis C Virus

被引:12
|
作者
Shores, Nathan J. [1 ]
Dodge, Jennifer L. [2 ]
Feng, Sandy [2 ]
Terrault, Norah A. [2 ]
机构
[1] Tulane Univ, New Orleans, LA 70118 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
FIBROSIS PROGRESSION; RACIAL-DIFFERENCES; UNITED-STATES; SURVIVAL; OUTCOMES; GRAFT; INFECTION; IMPACT; IL28B; HCV;
D O I
10.1002/hep.26478
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
African American (AA) liver transplant (LT) recipients with hepatitis C virus (HCV) have higher rates of graft loss than other racial/ethnic groups. The Donor Risk Index (DRI) predicts graft loss but is neither race- nor disease-specific and may not be optimal for assessing donor risk for AA HCV-positive LT recipients. We developed a DRI for AA with HCV with the goal of enhancing graft loss predictions. All U.S. HCV-positive adult AA first deceased donor LTs surviving 30 days from March 2002 to December 2009 were included. A total of 1,766 AA LT recipients were followed for median 2.8 (interquartile range [IQR] 1.3-4.9) years. Independent predictors of graft loss were donor age (40-49 years: hazard ratio [HR] 1.54; 50-59 years: HR 1.80; 60+ years: HR 2.34, P<0.001), non-AA donor (HR 1.66, P<0.001), and cold ischemia time (CIT) (HR 1.03 per hour >8 hours, P=0.03). Importantly, the negative effect of increasing donor age on graft and patient survival among AAs was attenuated by receipt of an AA donor. A new donor risk model for AA (AADRI-C) consisting of donor age, race, and CIT yielded 1-year, 3-year, and 5-year predicted graft survival rates of 91%, 77%, and 68% for AADRI <1.60; 86%, 67%, and 55% for AADRI 1.60-2.44; and 78%, 53%, and 39% for AADRI >2.44. In the validation dataset, AADRI-C correctly reclassified 27% of patients (net reclassification improvement P=0.04) compared to the original DRI. Conclusion: AADRI-C identifies grafts at higher risk of failure and this information is useful for risk-benefit discussions with recipients. Use of AA donors allows consideration of older donors. (Hepatology 2013;58:1263-1269)
引用
收藏
页码:1263 / 1269
页数:7
相关论文
共 50 条
  • [21] Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection
    Grant, Jennifer L.
    Hawkins, Claudia
    Brooks, Hannah
    Palella, Frank J., Jr.
    Koppe, Sean W. P.
    Abecassis, Michael M.
    Stosor, Valentina
    AIDS, 2016, 30 (01) : 93 - 98
  • [22] Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus
    Zalawadiya, Sandip K.
    Lindenfeld, JoAnn
    Shah, Ashish
    Wigger, Mark
    Danter, Matthew
    Brinkley, D. Marshall
    Menachem, Jonathan
    Punnoose, Lynn
    Balsara, Keki
    Sacks, Suzanne Brown
    Ooi, Henry
    Perri, Roman
    Awad, Joseph
    Smith, Sarah
    Fowler, Rachel
    O'Dell, Heather
    Darragh, Callie
    Ruzevich-Scholl, Shelly
    Schlendorf, Kelly
    ASAIO JOURNAL, 2020, 66 (05) : 553 - 558
  • [23] Clinical Efficacy of Simultaneous Splenectomy in Liver Transplant Recipients With Hepatitis C Virus
    Morimoto, H.
    Ishiyama, K.
    Ishifuro, M.
    Ohira, M.
    Ide, K.
    Tanaka, Y.
    Tahara, H.
    Teraoka, Y.
    Yamashita, M.
    Abe, T.
    Hashimoto, S.
    Hirata, F.
    Tanimine, N.
    Saeki, Y.
    Shimizu, S.
    Sakai, H.
    Yano, T.
    Tashiro, H.
    Ohdan, H.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (03) : 770 - 773
  • [24] Hepatitis C virus core antigen testing in liver and kidney transplant recipients
    Heidrich, B.
    Pischke, S.
    Helfritz, F. A.
    Mederacke, I.
    Kirschner, J.
    Schneider, J.
    Raupach, R.
    Jaeckel, E.
    Barg-Hock, H.
    Lehner, F.
    Klempnauer, J.
    von Hahn, T.
    Cornberg, M.
    Manns, M. P.
    Ciesek, S.
    Wedemeyer, H.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (11) : 769 - 779
  • [25] Treatment of Hepatitis C in Liver Transplant Recipients
    Gordon, Fredric D.
    Kwo, Paul
    Vargas, Hugo E.
    LIVER TRANSPLANTATION, 2009, 15 (02) : 126 - 135
  • [26] Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients
    Gutierrez, Julio A.
    Carrion, Andres F.
    Avalos, Danny
    O'Brien, Christopher
    Martin, Paul
    Bhamidimarri, Kalyan Ram
    Peyton, Adam
    LIVER TRANSPLANTATION, 2015, 21 (06) : 823 - 830
  • [27] The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients
    Kuntzen, Christian
    Bagha, Zohaib
    CLINICS IN LIVER DISEASE, 2022, 26 (02) : 291 - 312
  • [28] Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients
    Campos-Varela, Isabel
    Ignacio Esteban, Juan
    Bes, Marta
    Dopazo, Cristina
    Allende, Helena
    Rodriguez-Frias, Francisco
    Teresa Salcedo, Maria
    Sauleda, Silvia
    Charco, Ramon
    Guardia, Jaime
    Esteban, Rafael
    Castells, Lluis
    ANNALS OF HEPATOLOGY, 2014, 13 (02) : 219 - 230
  • [29] Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil
    Pacheco, Larissa Sgaria
    Ventura, Pedro Enrico
    Kist, Roger
    Garcia, Valter Duro
    Meinerz, Gisele
    Tovo, Cristiane Valle
    Cantisani, Guido Pio Cracco
    Zanotelli, Maria Lucia
    Mucenic, Marcos
    Keitel, Elizete
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2023, 65
  • [30] Donor Livers with Steatosis Are Safe To Use in Hepatitis C Virus-Positive Recipients
    Burra, Patrizia
    Loreno, Massimiliano
    Russo, Francesco Paolo
    Germani, Giacomo
    Galligioni, Alessandra
    Senzolo, Marco
    Cillo, Umberto
    Zanus, Giacomo
    Fagiuoli, Stefano
    Rugge, Massimo
    LIVER TRANSPLANTATION, 2009, 15 (06) : 619 - 628